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Potent single-domain antibodies that arrest
respiratory syncytial virus fusion protein in its
prefusion state
Iebe Rossey1,2,*, Morgan S.A. Gilman3,*, Stephanie C. Kabeche3, Koen Sedeyn1,2, Daniel Wrapp3, Masaru
Kanekiyo4, Man Chen4, Vicente Mas5, Jan Spitaels1,2, José A. Melero5, Barney S. Graham4, Bert Schepens1,2,
Jason S. McLellan3 & Xavier Saelens1,2

Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral
membrane protein that is essential for infection. The prefusion conformation of RSV F is
considered the most relevant target for antiviral strategies because it is the fusion-competent
form of the protein and the primary target of neutralizing activity present in human serum.
Here, we describe two llama-derived single-domain antibodies (VHHs) that have potent
RSV-neutralizing activity and bind selectively to prefusion RSV F with picomolar afﬁnity.
Crystal structures of these VHHs in complex with prefusion F show that they recognize
a conserved cavity formed by two F protomers. In addition, the VHHs prevent RSV replication
and lung inﬁltration of inﬂammatory monocytes and T cells in RSV-challenged mice. These
prefusion F-speciﬁc VHHs represent promising antiviral agents against RSV.
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uman respiratory syncytial virus (RSV) is the leading
cause of lower respiratory tract infections in children
under the age of ﬁve throughout the world. It is estimated
that RSV infects about 33.8 million children in this age group
annually, of which more than 3 million require hospitalization
due to severe bronchiolitis or pneumonia1. Reinfections occur
regularly throughout life because natural infection offers only
limited immunity2. RSV is also recognized as a major pathogen
for the elderly, with a disease burden similar to that of seasonal
inﬂuenza3. Thus, there is an urgent need for therapeutics that
can reduce disease caused by RSV.
Despite its medical importance and decades of intense
research, there is still no licensed RSV vaccine nor an effective
antiviral. The humanized monoclonal antibody (mAb) palivizumab (Synagis) reduces hospitalizations when administered
prophylactically, but its high cost and limited efﬁcacy restrict
its use to high-risk infants4. Palivizumab neutralizes RSV by
binding to the fusion (F) protein and preventing fusion
of the viral membrane with the host-cell membrane5. RSV F is
a class I fusion protein that is expressed as an inactive precursor,
F0, which is cleaved at two sites by a furin-like protease, leading
to the formation of the disulﬁde-linked F2 (N-terminal) and
F1 (C-terminal) subunits, which associate and trimerize to form
the mature prefusion F protein6. Upon triggering, prefusion
F partially refolds and inserts its hydrophobic fusion peptide into
the membrane of the target cell. Fusion of the viral and
host-cell membranes is facilitated by further refolding of the
F protein into the stable postfusion conformation. Small
molecules that bind to RSV F and prevent its structural remodelling, or F-speciﬁc antibodies that interfere with membrane
fusion, can block RSV infection7–10. Such compounds are being
clinically developed.
Palivizumab binds to antigenic site II on RSV F, which is one
of two well-characterized antigenic sites that are present on
both the pre- and postfusion conformations. However, intensive
screening for human mAbs that potently neutralize RSV has
resulted in the isolation of prefusion F-speciﬁc antibodies
with more robust neutralizing activity than palivizumab9,10.
Recently, RSV F was successfully stabilized in its prefusion
conformation through the introduction of an intraprotomeric
disulﬁde bond, cavity-ﬁlling mutations and a trimerization
motif. This reagent, called DS-Cav1, has been instrumental in
revealing that the vast majority of RSV-neutralizing
immunoglobulins in human sera selectively bind to F in its
prefusion conformation11–13.
In addition to conventional antibodies, heavy-chain-only
antibodies also exist in nature, for example, in both camelids
and sharks14,15. The isolated antigen-recognition domains
of these unusual antibodies are known as single-domain
antibodies (VHHs). VHHs are very well suited for the
development of therapeutics because of their small size, ease
of production and physical stability that allows alternative routes
of administration such as pulmonary delivery by nebulization16.
A number of clinical trials are already ongoing with recombinant
VHHs for the treatment of rheumatoid arthritis, cancer and
infectious diseases17–19. ALX-0171 is an RSV-neutralizing
VHH that binds to an epitope on RSV F that is similar to that
of palivizumab19. In a phase I/IIa trial, hospitalized RSV-infected
children were treated daily for three consecutive days with
ALX-0171 delivered by an inhalation device16. The treatment was
safe and did not lead to any treatment-related serious adverse
events. Interestingly, the study also revealed a trend towards
a therapeutic effect, based on reduced viral loads in nasal
swabs and clinical symptoms. In contrast, a similar trial with
motavizumab—an afﬁnity matured version of palivizumab—did
not alter viral replication or improve clinical symptoms when
2

administered after infection20. This different outcome might
be explained by the direct delivery of ALX-0171 to the lungs
whereas only about 0.2% of systemically administered antibody
ends up in the lung lumen21.
We hypothesized that a prefusion-speciﬁc VHH would have
a much stronger antiviral effect than a conformation-independent
VHH like ALX-0171. Here, we present the isolation and
characterization of two llama-derived VHHs that potently
neutralize RSV A and B subtypes and selectively bind prefusion
F with picomolar afﬁnity. Structural studies reveal that these
two VHHs bind to a conserved quaternary epitope composed
of two F protomers. Furthermore, prophylactic treatment of
mice with these VHHs potently controlled RSV infection
and associated inﬂammation.
Results
Isolation of VHHs with exceptional RSV-neutralizing activity.
To obtain VHHs that selectively bind to the prefusion
conformation of RSV F, a llama was immunized with recombinant F protein that was stabilized in the prefusion conformation,
that is, DS-Cav1 (ref. 13). Plasma prepared after six weekly
immunizations with prefusion F had potent RSV subtype A and
B neutralizing activity (Supplementary Fig. 1). Peripheral blood
mononuclear cells were isolated from the prefusion F-immunized
llama and used to generate a VHH phage-display library.
One round of panning on immobilized prefusion F protein
resulted in a 140-fold enrichment in candidate prefusion
F-binding phages. In a ﬁrst approach to select RSV-neutralizing
VHHs, we randomly selected 90 clones from this enriched
population and tested binding to RSV F protein by ELISA.
Thirty-seven clones expressed VHH that bound to either pre- or
postfusion F protein (FDFP)22; twenty-eight of these had a unique
sequence and were subsequently expressed in Pichia pastoris.
RSV A2-neutralizing activity was present in the crude growth
medium of P. pastoris clones 1, 4, 8, 13 and 44, which
were retained for further analysis (Supplementary Fig. 2a).
In an alternative approach, the VHH cDNA inserts obtained
after one round of panning on prefusion F were cloned as
a pool into the P. pastoris expression vector and the resulting
library was used to transform P. pastoris. The crude culture
growth medium of individual P. pastoris transformants was then
tested for RSV-neutralizing activity. One candidate, named
F-VHH-L66, displayed clear RSV A2-neutralizing activity
(Supplementary Fig. 2b). We puriﬁed the VHHs from the culture
supernatant of the selected P. pastoris transformants for further
analysis. All six puriﬁed VHHs (F-VHH-1, -4, -8, -13, -44 and
-L66) neutralized RSV A and RSV B subtypes in vitro,
with F-VHH-4 and F-VHH-L66 exhibiting the most potent
neutralization, with an IC50 value below 0.1 nM for both
RSV strains (Fig. 1a,b). These two VHHs were therefore selected
for further characterization. Sequence analysis of F-VHH-4 and
-L66 revealed an identical complementarity-determining region
(CDR) 1, a similar CDR2, but a very different CDR3 (Fig. 1c and
Supplementary Fig. 3). F-VHH-4 and -L66 both have a cysteine
residue at position 100c in the CDR3 and at position 50 in
the CDR2. A disulﬁde bond between the CDR3 and a residue
at position 33 or 50 is a hallmark of VHHs and helps to stabilize
the extended CDR3 loop conformation23.
To assess the antiviral potency of the VHHs in more
detail, RSV-neutralization assays were performed in which
F-VHH-4 and -L66 were compared with several F-speciﬁc
mAbs (palivizumab, motavizumab, D25 and AM22)9,24,25.
Remarkably, despite their monovalent character, F-VHH-4 and
-L66 neutralized RSV A and B with picomolar IC50 values,
which are similar to or lower than those for the bivalent prefusion
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Figure 1 | F-VHHs with potent RSV-neutralizing activity. RSV-neutralizing activity by F-VHHs. (a) RSV A2 (50 pfu per well) or (b) RSV B49 (40 pfu per
well) was preincubated with different concentrations of VHH before infection of Vero cells. Three days later, the viral plaques were stained with polyclonal
anti-RSV serum. (c) Amino acid sequences of F-VHH-4 and F-VHH-L66 with Kabat numbering. The complementarity-determining regions (CDRs) are
boxed. Cysteines in CDR2 and CDR3 are in bold. (d) RSV A2 (30 pfu per well) plaque-reduction activity of F-VHH-4 and F-VHH-L66 compared with mAbs.
The Ctrl-VHH is speciﬁc for an irrelevant target. (e) IC50 values of F-VHHs and mAbs against RSV A2 and RSV B49 as determined by plaque-reduction
assay. Mean values±s.d. from four (VHHs), three (D25) or two (palivizumab, motavizumab and AM22) repeat experiments are depicted for RSV A. Mean
values±s.d. from two experiments are depicted for RSV B. ND: Not determined. (f) Dilution series of VHHs and mAbs were added to HEp-2 cells that had
been preincubated with RSV A2 (25 pfu per well) at 4 °C for 2 h, allowing viral attachment. After 2 h at 37 °C, the VHHs or antibodies were washed away
and infection was allowed during two days at 37 °C after which the plaques were stained. Antibody, 65 is a mouse IgG2a monoclonal antibody that is
speciﬁc for an irrelevant antigen.

F-speciﬁc mAbs D25 and AM22 (Fig. 1d,e). The VHHs were
also tested in a neutralization assay against a set of clinical
RSV isolates and a set of molecular clones built on the RSV Line
19 backbone, but with F and G derived from primary clinical
isolates. These strains were as susceptible as the lab strains
to neutralization by the VHHs (Supplementary Table 1 and
Supplementary Fig. 4).
In HEp-2 cells the F protein is involved in both viral
attachment and membrane fusion26–30. We therefore

investigated if the VHHs could prevent infection after
attachment of viral particles to the cells. Similar to palivizumab
and D25, F-VHH-4 and F-VHH-L66 prevented infection
when added after virion attachment (Fig. 1f). However,
mixing of RSV with the neutralizing VHHs before infection
did not hinder viral attachment to HEp-2 target cells, indicating that F-VHH-4 and -L66 inhibit RSV in vitro by
blocking membrane fusion post-attachment (Supplementary
Fig. 5).
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Figure 2 | F-VHH-4 and -L66 bind a similar epitope on prefusion F that partially overlaps with four previously characterized epitopes. (a) Surface
plasmon resonance (SPR) sensorgrams for the binding of F-VHH-4 (left) and F-VHH-L66 (right) to immobilized prefusion F. A buffer-only sample was
injected over the prefusion F and reference ﬂow cells, followed by 2-fold serial dilutions of F-VHH-4 or F-VHH-L66 ranging from 5 nM to 39.1 pM, with a
duplication of the 1.25 nM concentration. The data were double-reference subtracted and ﬁt to a 1:1 binding model (red lines). (b) Prefusion F protein was
immobilized on AR2G biosensors. The biosensors were dipped in competitor antibodies followed by analyte antibodies. Per cent inhibitions were deﬁned by
comparing binding maxima of the analyte antibody in the absence and presence of each competitor. NB, no binding.
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Figure 3 | Thr50Asn substitution in F2 enables viral escape from F-VHH-4 and F-VHH-L66 neutralization. F-VHH-4 escape virus (left panel) or
RSV A2 (right panel) (25 PFU) was incubated for 30 min at 37 °C with different concentrations of the indicated VHH or mAb before addition to a monolayer
of Vero cells. Three days later, cells were ﬁxed and stained with polyclonal anti-RSV serum to visualize the plaques (enumerated in the Y axis).

VHHs bind a unique prefusion F-speciﬁc epitope. To investigate whether the neutralizing VHHs speciﬁcally recognize
the prefusion conformation of RSV F, the binding kinetics
to recombinant pre- and postfusion F proteins were measured
by surface plasmon resonance (SPR). The VHHs bound tightly
to prefusion-stabilized F, whereas no binding to postfusion
F could be detected (Fig. 2a and Supplementary Fig. 6). F-VHH-4
bound to immobilized prefusion RSV F with an equilibrium
dissociation constant (KD) lower than 18 pM. The off-rate
was extremely slow and outside the range measurable by
SPR, therefore, the upper limit of the KD was estimated using
the measured association rate constant (5.7  105 M 1 s 1)
and the lower limit of detection for the dissociation rate
constant (1  10 5 s 1). F-VHH-L66 also bound to prefusion
F with sub-nanomolar afﬁnity. However, compared with
F-VHH-4, the F-VHH-L66 association rate constant was lower
4

(3.3  105 M 1 s 1) and the dissociation rate constant
was higher (5  10 5 s 1), resulting in a KD of 154 pM. Binding
of the VHHs to cells transfected with a codon-optimized
F-expression plasmid and to RSV-infected cells was also
observed (Supplementary Figs 7 and 8), demonstrating that
the VHHs recognize full-length F in the context of biological
membranes.
To gain more insight into the epitopes that are targeted
by F-VHH-4 and -L66, we performed cross-competition binding
experiments using biolayer interferometry and a set of mAbs
with known epitopes. This analysis revealed that the two
VHHs competed with each other for binding to immobilized
prefusion F and thus likely bound to overlapping epitopes
(Fig. 2b). Binding by D25, which recognizes site Ø on prefusion F,
was not hindered by F-VHH-4 or -L66, which suggests
that neither VHH bound to this site. In contrast, palivizumab,
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Table 1 | Crystallographic data collection and reﬁnement statistics.

PDB ID
Data collection
Space group
Cell dimensions
a, b, c (Å)
a, b, g (°)
Resolution (Å)
Rmerge
I/sI
CC1/2
Completeness (%)
Redundancy
Reﬁnement
Resolution (Å)
Unique reﬂections
Rwork/Rfree (%)
No. atoms
Protein
Glycan (NAG)
Ion (PO4)
Water
B-factors
Protein
Glycan (NAG)
Ion (PO4)
Water
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Ramachandran
Favoured (%)
Allowed (%)
Outliers (%)

F-VHH-4
5TP3

F-VHH-4–prefusion F
5TOJ

F-VHH-L66–prefusion F
5TOK

P212121

P3221

P3121

47.7, 47.8, 149.8
90, 90, 90
34.5–1.9
(1.92–1.87)
0.118 (1.125)
11.1 (2.1)
0.995 (0.465)
100 (100)
6.6 (5.6)

173.2, 173.2, 153.3
90, 90, 120
38.0–3.3
(3.43–3.30)
0.188 (1.081)
9.2 (2.1)
0.995 (0.545)
99.9 (100)
7.4 (7.5)

138.9, 139.9, 221.9
90, 90, 120
50.4–3.8
(4.06–3.80)
0.332 (1.246)
5.2 (1.5)
0.975 (0.549)
99.9 (100)
5.3 (5.5)

34.5–1.9
(1.94–1.87)
28,958 (2,824)
17.0/20.8

38.0–3.3
(3.38–3.30)
40,277 (2,821)
18.4/23.4

50.4–3.8
(3.95–3.80)
24,981 (2,726)
24.8/28.6

1,910
0
0
143

14,082
42
0
0

13,952
42
5
0

25.7
—
—
29.4

94.5
97.3
—
—

124.0
117.9
149.0
—

0.007
0.81

0.005
1.20

0.007
1.13

97.2
2.9
0

96.5
3.3
0.2

96.6
3.0
0.4

Values in parentheses are for the highest-resolution shell.

AM14, MPE8 and 101F interfered with binding of the two VHHs
to prefusion F and vice versa, suggesting that the VHH epitope
is located in the vicinity of the binding sites of these four
antibodies, approximately midway between the apex of the trimer
and the viral membrane.
To further narrow down the binding site of the VHHs,
we selected for viruses resistant to F-VHH-4 and -L66.
Two rounds of selection in the presence of F-VHH-L66 and
four rounds of selection in the presence of F-VHH-4 led to
the isolation of a single type of escape variant that
had a threonine to asparagine substitution at position 50 in the
F2 subunit. F-VHH-L66 failed to neutralize this mutant virus,
whereas this virus was still susceptible to inhibition by F-VHH-4,
although this required 300-fold more F-VHH-4 compared
with the parental virus (Fig. 3). Thr50 resides at the ﬂoor of
a cavity in prefusion F that is surrounded by the epitopes
of palivizumab, AM14 and 101F5,31,32, suggesting that both
VHHs bind to this cavity.
F-VHHs bind a cavity formed by two F protomers. To precisely
deﬁne the epitopes recognized by F-VHH-4 and -L66, their
crystal structures in complex with prefusion F were determined
to 3.3 and 3.8 Å resolution, respectively (Table 1). In addition,
the crystal structure of unbound F-VHH-4 was determined to

1.9 Å resolution (Table 1 and Supplementary Fig. 9). The complex
structures revealed that despite substantial differences in
CDR3 sequence, F-VHH-4 and -L66 bind in a nearly identical
manner to a cavity formed by the boundary of two F protomers
(Fig. 4a). This cavity is bordered by antigenic site II of one
protomer and antigenic site IV of the neighbouring protomer,
and the location of this epitope between the binding sites
of palivizumab, 101F and AM14 explains the ability of the
VHHs to compete with each of these antibodies (Fig. 2b and
Supplementary Fig. 10). This epitope has also been mapped
by mutagenesis as the likely epitope for MPE8, which
cross-neutralizes RSV, human metapneumovirus (hMPV)
and pneumonia virus of mice (PVM)10. The VHHs, however,
while being broadly neutralizing for RSV, did not neutralize
hMPV (Supplementary Table 2).
F-VHH-4 and -L66 each bury nearly 1,200 Å2 on prefusion F,
with approximately 60% of the total buried surface area on one
protomer and 40% on the adjacent protomer (Fig. 4b). The
distribution of the VHH epitopes among the two protomers
suggested that F-VHH-4 and -L66 may be trimer-speciﬁc, which
is a property that thus far has only been described for antibody
AM14 (ref. 31). To conﬁrm the trimer-speciﬁcity of the VHHs,
their binding kinetics for monomeric prefusion F were measured
by SPR (Supplementary Fig. 11). The KD of F-VHH-4 binding
to monomeric prefusion F was 23 nM, which is over
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Figure 4 | F-VHHs bind an epitope formed by two protomers of prefusion F. (a) Superposition of the crystal structures of three F-VHH-4 s (blue) and
three F-VHH-L66s (orange) bound to prefusion RSV F, viewed from the side (left) and the top (right). (b) Close-up of the VHH-binding cavity, viewed from
the side (left) and from the bottom (right). The VHH epitope is outlined with a dotted black line in the side view. The CDR2s and CDR3s of both VHHs are
shown as tubes.
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Figure 5 | F-VHHs make direct contacts with residues on two neighbouring protomers of prefusion F. Close-up of the CDR3 and CDR2 from
(a) F-VHH-4 and (b) F-VHH-L66 bound to prefusion F. CDR2 and CDR3 are shown as tubes with the N- and C-termini labelled. Side-chains and main-chain
involved in hydrogen bonding are shown as sticks, with hydrogen bonds depicted as black dotted lines. Residues of the F protein are labelled.

1,000-fold weaker than the afﬁnity measured for trimeric
prefusion F. No binding of F-VHH-L66 to monomeric prefusion
F was detected, even at the highest concentration tested (500 nM)
(Supplementary Fig. 11). Both VHHs were also able to bind and
trap wild-type F protein ectodomain in the trimeric prefusion
conformation (Supplementary Fig. 12). Therefore, both VHHs
have a high selectivity for the trimeric state of prefusion F.
The CDR3s of F-VHH-4 and -L66 are submerged in
the interprotomeric cavity and therefore mediate the majority
6

of the interactions with RSV F (Fig. 5 and Supplementary
Table 3). The main chain of both F-VHH-4 and -L66 forms
a hydrogen bond with Thr50 of F2, the residue mutated in
the escape viruses isolated for both VHHs. A number of hydrogen
bonds are also formed between the CDR3 and the antiparallel
b-strands that neighbour antigenic site IV. The CDR3 of each
VHH is disulﬁde-linked to CDR2, which hydrogen bonds
with the a7 helix of antigenic site II (Fig. 5). Upon membrane
fusion, the domains of each RSV F protomer contacted by the
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Discussion
Our aim was to obtain molecules with very high RSV-neutralizing
activity that could be developed as a therapeutic for the treatment
of RSV infections. We describe a new class of VHHs that bind
speciﬁcally to the prefusion conformation of the RSV F protein.
Such VHHs were obtained by the immunization of a llama with
a soluble prefusion-stabilized F protein combined with an
RSV-neutralization-based screening strategy. The resulting VHHs
display broad RSV-neutralizing activity, bind speciﬁcally and
with high afﬁnity to the prefusion conformation of F and inhibit
RSV replication in vivo. The potent RSV-neutralizing activity
of the F-VHHs correlates with their ultra-high afﬁnity for
the prefusion F protein. By tightly binding to an epitope that
is only present on the trimeric prefusion conformation, the
VHHs presumably interfere with the transition of the F protein
from the prefusion to the postfusion state, thereby preventing
fusion with the host cell.
F-VHH-4 and F-VHH-L66 have only 5 out of 15 amino
acids in common in their CDR3. Yet, F-VHH-4 and -L66 bind
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F-VHHs reduce replication of RSV in vivo. In a ﬁnal set
of experiments, we evaluated the protective potential of F-VHH-4
and -L66 in vivo. Both F-VHHs strongly reduced virus replication
when administered intranasally to BALB/c mice at a dose of
30 mg (1.5 mg kg  1) before challenge with RSV (Supplementary
Fig. 14). We selected F-VHH-4 for subsequent animal experiments because it has a slightly higher neutralizing activity than
F-VHH-L66. Intranasal administration of 10 mg (0.5 mg kg  1)
F-VHH-4 or palivizumab to BALB/c mice 4 h before challenge
with 1  106 PFU of RSV A2 resulted in undetectable levels of
virus in the lungs and the bronchoalveolar lavage on day ﬁve after
challenge (Fig. 6a and Supplementary Fig. 15). This apparent lack
of virus in the lungs of F-VHH-4- or palivizumab-treated mice
could be due to an in vitro effect of the remaining VHH or
antibody in the lung homogenates. Therefore, viral RNA was
quantiﬁed by an RSV-speciﬁc RT-qPCR. The lungs of mice
treated with F-VHH-4 were negative or borderline positive for
RSV RNA, whereas the relative amount of RSV RNA indicated at
least a 170-fold higher viral load in samples from palivizumabtreated mice compared with F-VHH-4-treated mice (Fig. 6b).
Finally, we also assessed the effect of F-VHH-4 treatment on the
inﬂux of immune cells in the lungs of RSV A2-challenged mice
ﬁve days after infection. In contrast to mice treated with CtrlVHH before challenge, mice treated with F-VHH-4 or palivizumab had signiﬁcantly less alveolar inﬂux of dendritic cells,
monocytes, and CD8 þ and CD4 þ T lymphocytes (Fig. 6c).
Lowering the amount of F-VHH-4 to 1 mg per mouse resulted in
the same protective effect (Supplementary Fig. 16).

**
**

Log10 lung RSV titer (PFU/lung)

VHHs undergo a rigid-body movement that causes their relative
positions to change substantially between the prefusion and
postfusion states. Superposition of the postfusion F structure
onto the VHH-bound prefusion structures reveals a signiﬁcant
clash between the loop connecting a6 and a7 of postfusion F and
the CDR3 of either VHH (Supplementary Fig. 13). Therefore,
our structural data suggest that F-VHH-4 and -L66 neutralize
RSV and block fusion by preventing the movement of domains
required for conversion of prefusion RSV F to the postfusion
state. In addition, both VHHs bury approximately 100 Å2 on
the b4 strand, which dramatically rearranges to become a portion
of the a5 helix of postfusion F. Although the buried surface
area in this region is relatively small, these contacts may
also contribute to the prefusion speciﬁcity of the VHHs by
preventing the refolding of b4 during the transition from
prefusion to postfusion F.

Figure 6 | F-VHH-4 inhibits RSV A2 replication in mice. Groups of six
BALB/c mice were treated intranasally with 0.5 mg kg  1 of F-VHH-4,
palivizumab or Ctrl-VHH 4 h before infection with 1  106 RSV A2 or
PBS (mock). Five days after infection, the pulmonary RSV load was
determined by (a) plaque assay (dashed line represents the detection limit)
or (b) by quantiﬁcation of the amount of lung viral RNA using RT-qPCR.
Horizontal lines indicate medians. *Po0.05, **Po0.01 (Mann–Whitney
U-test). (c) Five days after infection, BAL ﬂuid was prepared and the
percentage of immune cells was determined by ﬂow cytometry. Bars
represent the average percentage of the indicated cell type±s.d. (n ¼ 6)
(AM, alveolar macrophages; DC, dendritic cells; Monoc, monocytes;
CD4, CD4 þ T cells; CD8, CD8 þ T cells; Neutr, neutrophils; Eosino,
eosinophils). *Po0.05, **Po0.01 (Mann–Whitney U-test).

closely overlapping epitopes in a nearly identical way. On
the nucleotide level, the VHHs are 94% identical, indicating that
they probably emerged from the same recombined germline
sequences. If so, it is remarkable that two very different paths
of afﬁnity maturation converge to highly similar modes of
binding. Crystallization studies showed that the CDR3 of both
VHHs bind into a cavity formed by two protomers. This
illustrates the tendency of VHHs to preferably bind clefts
or cavities, whereas conventional antibodies in general bind
either ﬂat surfaces or extruding epitopes33. The epitope of
F-VHH-4 and F-VHH-L66 overlaps with the epitope mapped
by mutagenesis for the broadly neutralizing antibody MPE8,
which has neutralizing activity against human and bovine
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RSV, hMPV and PVM10. Nevertheless, the VHHs do not
neutralize hMPV. RSV and hMPV F proteins have only 33%
overall amino acid sequence identity34, yet a substantial area of
the surmised MPE8 epitope is conserved between the two viruses.
Although the VHHs bind to a similar region, they
make crucial contacts with a number of residues that are not
conserved between RSV F and hMPV F, explaining the lack
of hMPV neutralization by the F-VHHs. Thus, in this case there
appears to be a trade-off between the potency of the VHHs and
the breadth of MPE8.
We addressed the in vitro escape potential of RSV in the
presence of the VHHs. F-VHH-4 and F-VHH-L66 escape viruses
had a single mutation resulting in a substitution of Thr50,
which is located at the bottom of the cavity bound by the
VHHs. Although resistant to F-VHH-L66, this virus could still
be neutralized by F-VHH-4, albeit with 300-fold lower efﬁciency.
The presence of three consecutive serine residues in the CDR3
of F-VHH-4 could lead to more ﬂexibility of this loop compared
with that of F-VHH-L66 and allow F-VHH-4 to bind to
an altered conformation of prefusion F. Although the possibility
of selecting for an escape mutant could raise concerns for
the clinical use of these VHHs, the escape virus was severely
attenuated as it was impossible to grow the virus to substantial
amounts to make high-titre virus stocks.
Other VHHs against RSV F have been described recently19,35.
Nb017, for example, is a VHH developed by Ablynx that binds
to antigenic site II of RSV F19. F-VHH-4 outperforms Nb017
by 15,000- and 180,000-fold on RSV A and RSV B neutralization
respectively, reﬂecting the higher potency of prefusion-speciﬁc
antibodies compared with antibodies that bind both
conformations of F. To increase its neutralizing activity, Nb017
was re-formatted into a trivalent VHH named ALX-0171.
However, monovalent F-VHH-4 and -L66 already display
higher RSV A- and B- neutralizing activity than that reported
for ALX-0171. In addition, the small size of monovalent
VHHs may reduce their potential immunogenicity and facilitate
penetration of the mucus layer that lines the respiratory
epithelium to reach RSV-infected cells. It is also straightforward to link a monovalent VHH to other carriers, such
as a VHH that binds to another epitope in RSV or to a protein
with an effector function of interest.
A phase I/IIa clinical trial with inhaled ALX-0171 in
hospitalized RSV-infected children indicated that the drug
was safe. The trial also indicated that treatment with this trivalent
pre- and postfusion F-reactive VHH could reduce viral replication and symptoms in the infected children. By selectively
targeting prefusion F, for example with the VHHs described
here, the antiviral impact in patients may be improved, which
could result in a more robust clinical beneﬁt in a treatment setting
of RSV-infected patients. As the vast majority of RSV-infected
infants are hospitalized at or after the peak of viral replication
and disease, early RSV detection followed by rapid antiviral
treatment remains key to reduce symptoms and prevent
hospitalization of patients. Nebulization of F-VHH-4 as soon
as possible after RSV conﬁrmation offers the additional advantage
that the antiviral is delivered directly to the site of infection.
Developing new antibody-based drugs for respiratory infections in a VHH format has a number of advantages. Production
and puriﬁcation are inexpensive, straight-forward and can be
performed in organisms that are generally regarded as safe
and without the use of animal-derived products. In addition,
due to their small size, high stability and solubility, VHHs can
be easily administered via inhalation, directly to the site of
viral infection. The in vitro and in vivo results reported here
support further testing of F-VHH-4 and F-VHH-L66 as novel
therapeutics against RSV.
8

Methods
Study design. It was our aim to develop efﬁcient RSV-neutralizing VHHs that
bind to the prefusion conformation of the F protein. Binding and neutralizing
characteristics of the VHHs were analysed on HEK293T cells, Vero cells, HEp-2 or
A549 cells. In vivo assays were performed in BALB/c mice. All animal experiments
were conducted with the approval of the Ethical committee of the faculty of
Sciences (University of Ghent, Belgium, EC number 2015-019).
Generation of prefusion F-speciﬁc VHHs. A llama was immunized
subcutaneously six times with 167 mg DS-Cav1 each time at weekly intervals.
The animal facility operates under the Flemish Government License Number
LA1 700601. All experiments were done under conditions speciﬁed by law and
authorized by the Institutional Ethical Committee on Experimental Animals
(Ethical application 13-601-1).The DS-Cav1 protein was adjuvanted with
poly (I:C) (Invivogen, 375 mg per injection) for the ﬁrst two immunizations and
with Gerbu LQ#3000 for the last four immunizations. One week after the last
immunization 100 ml anticoagulated blood was collected for the preparation of
peripheral blood lymphocytes. Total RNA from peripheral blood lymphocytes
was used as template for ﬁrst strand cDNA synthesis with oligodT primer.
Using this cDNA, the VHH encoding sequences were ampliﬁed by a nested
PCR using ﬁrst the call 01 and call 02 primers (50 GTCCTGGCTGCTCT
TCTACAAGG30 , 50 GGTACGTGCTGTTGAACTGTTCC30 ) and next the A6E and
38 primer (50 GATGTGCAGCTGCAGGAGTCTGGA/GGGAGG30 ;
50 GGACTAGTGCGGCCGCTGGAGACGGTGACCTGGGT30 ). The resulting
PCR fragment was digested with PstI and NotI, and cloned into the PstI and
NotI sites of the phagemid vector pHEN4. Electrocompetent E. coli TG1 cells
were transformed with the recombinant pHEN4 vector. The resulting TG1 library
stock was infected with VCS M13 helper phage to obtain a library of
VHH-presenting phages.
One round of panning was performed on 20 mg of immobilized prefusion
F (DS-Cav1) in one well of a microtiter plate (type II, F96 Maxisorp, Nunc).
After blocking the prefusion F-coated well and an uncoated well used as
a negative control with SEA BLOCK blocking buffer (Thermo Scientiﬁc), phages
(1  1012 particles) were applied to these wells and incubated for 1 h at room
temperature. After washing, the retained phage particles were eluted by applying
a TEA-solution (14% triethylamine (Sigma) pH 10) for 10 min. Dissociated phages
were transferred to a tube with 1 M Tris-HCl pH 8. Tenfold serial dilutions of
the phages were used to infect TG1 cells, after which the bacteria were plated on
LB agar plates with 100 mg ml 1 ampicillin and 1% glucose.
Detection of F-speciﬁc VHHs in bacterial periplasm. After a single round of
panning, ninety colonies were randomly selected for further analysis by ELISA for
the presence of F-speciﬁc VHHs in their periplasm. The colonies were used
to inoculate 2 ml of terriﬁc broth (TB) medium with 100 mg ml 1 ampicillin in
24-well deep well plates. After a 5 h incubation step at 37 °C, VHH expression
was induced by adding isopropyl b-D-1-thiogalactopyranoside (IPTG) at
a concentration of 1 mM. The plates were subsequently incubated overnight at
37 °C while shaking. The next day, bacterial cells were pelleted, resuspended in
200 ml TES buffer (0.2 M Tris-HCl pH 8, 0.5 mM EDTA, 0.5 M sucrose) and
incubated at 4 °C for 30 min. Next, periplasmic extracts were prepared by adding
water to induce osmotic shock. After 1 h incubation at 4 °C and subsequent centrifugation, the supernatants were collected. Microtiter plates were coated overnight with either 100 ng F protein in the postfusion conformation (FDFP),
100 ng prefusion F (DS-Cav1) or bovine serum albumin (BSA, Sigma-Aldrich).
The coated microtiter plates were blocked with 1% milk powder in phosphatebuffered saline (PBS) and 100 ml of the periplasmic extract was added to the wells.
Bound VHHs were detected with anti-HA (1/2,000, MMS-101P Biolegend)
mAb and horseradish peroxidase (HRP)-linked anti-mouse IgG (1/2,000, NXA931,
GE Healthcare). After washing, 50 ml of TMB substrate (Tetramethylbenzidine,
BD OptEIA) was added to every well. The reaction was stopped by addition of 50 ml
of 1M H2SO4, after which the absorbance at 450 nM was measured with an iMark
Microplate Absorbance Reader (Bio Rad). All periplasmic fractions for which the
OD450 values obtained for prefusion or postfusion F were at least two times higher
than the OD450 values obtained for BSA were selected and grown in 3 ml of
LB medium with 100 mg ml  1 ampicillin for plasmid isolation using the QIAprep
Spin Miniprep kit (Qiagen). The cDNA sequence of the VHH was determined by
Sanger sequencing using the M13RS primer (50 CAGGAAACAGCTATGACC30 ).
Expression of VHHs in Pichia pastoris. To clone VHH sequences into a yeast
expression vector, the VHH coding sequences were PCR ampliﬁed from the
respective pHEN4 plasmids using the following forward and reverse primers
(50 GGCGGGTATCTCTCGAGAAAAGGCAGGTGCAGCTGCAGGAGTCT
GGG30 ; 50 CTAACTAGTCTAGTGATGGTGATGGTGGTGGCTGGAGACG
GTGACCTGG30 ). The resulting PCR products were digested with XhoI and
SpeI and ligated into XhoI/SpeI-digested pKai61 backbone. The origin of the
pKai61 vector is described in Schoonooghe et al.36. The VHH sequences are
cloned in frame with a slightly modiﬁed version of the S. cerevisiae a-mating
factor signal sequence. The encoded genes contain a C-terminal 6XHis tag and
are under control of the methanol inducible AOX1 promoter. The plasmid
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contains a Zeocine resistance marker for selection in bacterial as well as in
yeast cells. The vectors were linearized by PmeI before transformation of P. pastoris
strain GS115 using the condensed transformation protocol described by
Lin-Cereghino et al.37.
Puriﬁcation of VHHs produced by Pichia pastoris. Expression of VHH by
transformed P. pastoris clones was ﬁrst analysed in 2 ml cultures. On day
one, individual transformants were used to inoculate 2 ml of YPNG medium
(2% pepton, 1% Bacto yeast extract, 1.34% YNB, 0.1 M potassium phosphate
pH 6, 0.00004% biotine, 1% glycerol) with 100 mg ml 1 Zeocin (Life Technologies)
and incubated while shaking at 28 °C for 24 h. Next, cells were pelleted and the
YPNG medium was replaced by YPNM medium (2% peptone, 1% Bacto yeast
extract, 1.34% YNB, 0.1 M potassium phosphate pH 6, 0.00004% biotin,
1% methanol) to induce VHH expression. Cultures were incubated at 28 °C while
shaking for 48 h. Fifty microliters of 50% methanol was added to the cultures at 16,
24 and 40 h. After 48 h, the yeast cells were pelleted and the supernatant was
retained to assess the presence of VHH. To select VHHs with RSV-neutralizing
activity, serial dilutions of the crude YPNM supernatant from individual P. pastoris
transformants were tested in a plaque-reduction assay.
P. pastoris transformants that yielded high levels of VHH in the medium and
with high RSV-neutralizing activity were selected for scaling up using 100 or
300 ml P. pastoris cultures. Growth and methanol induction conditions and
harvesting of medium were similar as mentioned above for the 2 ml cultures. The
cleared medium was subjected to ammonium sulfate precipitation (80% saturation)
for 4 h at 4 °C. The insoluble fraction was pelleted by centrifugation at 20,000g and
solubilized in 10 ml HisTrap binding buffer (20 mM sodium phosphate,
0.5 M NaCl, 20 mM imidazole, pH 7.4) before puriﬁcation on a 1 ml HisTrap
HP column (GE Healthcare). Relevant fractions containing the VHH were pooled,
and concentrated with a Vivaspin column (5 kDa cutoff, GE Healthcare) and then
subjected to size-exclusion chromatography (Superdex 75). Fractions containing
the VHH were again pooled and concentrated and the concentration was
determined. The puriﬁed VHHs were aliquoted and stored at  80 °C until further
use.
Cells and viruses. HEp-2 cells (ATCC, CCL-23), Vero cells (ATCC, CCL-81),
HEK-293 T cells (a gift from Dr M. Hall, University of Birmingham, Birmingham,
UK) and A549 cells (ATCC, CCL-185) were grown in Dulbecco’s modiﬁed eagle
medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS),
2 mM L-glutamine, non-essential amino acids (Invitrogen, Carlsbad, CA, USA)
and 1 mM sodium pyruvate at 37 °C in the presence of 5% carbon dioxide. RSV A2,
an A subtype of RSV (ATCC, VR-1540, Rockville), RSV B49, a B subtype of
RSV (BE/5649/08 clinical strain38, source described in ref. 38, obtained from Prof
Marc Van Ranst, KU Leuven, Leuven, Belgium), RSV A Long (ATCC, VR-26, kind
gift from Dr Rik De Swart, Erasmus MC, Rotterdam, The Netherlands),
MAD/GM2_2/12, MAD/GM2_12/12, MAD/GM2_13/12, MAD/GM2_14/12,
MAD/GM3_10/14, MON/9/92 (primary RSV A strains, isolated in Madrid (MAD)
or Montevideo (MON)) and MAD/GM3_7/13 (a primary RSV B strain isolated
in Madrid) were propagated in HEp-2 cells and quantiﬁed on Vero cells by
plaque assay using goat anti-RSV serum (AB1128, Chemicon International).
Clinical isolates MAD/GM2_2/12, MAD/GM2_12/12, MAD/GM2_13/12,
MAD/GM2_14/12, MAD/GM3_10/14 and MON/9/92 represent at least 2 different
genotypes of antigenic group A39,40.
Plaque-reduction assay. A dilution series of the VHHs/mAbs was prepared
in Opti-MEM (Gibco), incubated with RSV for 30 min at 37 °C and used to
infect conﬂuent Vero cells. After 3 h, an equal volume of 1.2% avicel RC-851
Q(FMC Biopolymers) in DMEM medium supplemented with 2% FCS, 2 mM
L-glutamine, non-essential amino acids and 1 mM sodium pyruvate was added to
each well and the infection was allowed to continue at 37 °C for three days. Viral
infection was tested by immunostaining of the viral plaques with goat anti-RSV
serum (AB1128, Chemicon International) and horseradish peroxidase-conjugated
anti-goat IgG (SC2020, Santa Cruz). The plaques were visualized by applying
TrueBlue peroxidase substrate (KPL, Gaithersburg). For the post-attachment
neutralization assay, a dilution series of VHH/mAb was added to HEp-2 cells that
had been preincubated with RSV at 4 °C for 2 h. Control antibody 65 is a mouse
IgG2a monoclonal antibody speciﬁc for the inﬂuenza matrix protein 2 (ref. 41).
Recombinant mKate-RSV panel. The pSynkRSV-line19F, a BAC system
containing RSV cDNA was used to generate recombinant RSV antigenomes with
matched G and F genes from various RSV strains to recover new infectious
clones42. The panel of reconstructed recombinant mKate-RSV consists of ﬁve
RSV subtype A and three RSV subtype B viruses, which represent RSV lab
strains and primary isolates from distinct temporal and geographic regions.
The RSV subtype A panel comprises A2/D46 and A2/L19, which are laboratory
strains, and three primary strains: Riyadh 91/2009, 2-20 F/G and A1998/12-21.
RSV subtype B panel comprises one lab strain B/18537 and two primary isolates
TX11-56 and NH1276.

Fluorescence plate reader neutralization assay. Fluorescence plate reader
neutralization assay was performed as previously described13. A total of
2.4  104 HEp-2 cells per well in 30 ml culture medium were seeded in 384-well
black optical bottom plate (Nunc 384-well plates, Thermo Scientiﬁc). Serum
samples or antibodies (1 mg ml 1) were diluted four-fold for 12 dilutions starting
from 1:10, equal volume of recombinant mKate-RSV (subtype A and subtype B)
was added and mixed, incubated at 37 °C for 1 h, then 50 ml mixture of sample and
virus was added to cells and incubated at 37 °C for 22–24 h. After incubation, assay
plate was measured for ﬂuorescence intensity in microplate reader at Ex 588 nm
and Em 635 nm (SpectraMax Paradigm, molecular devices). For the 96-well plate
format, 5  104 cells per well in 100 ml of culture medium were seeded in a 96-well
plate, 100 ml mixtures of sample and virus were added to the plate. Virus inhibition
was measured as the reduction of ﬂuorescence of samples comparing to virus
control. Data was analysed and EC50 was calculated by curve ﬁtting with
GraphPad Prism software (GraphPad Software).

Attachment assay. RSV A2 (1  107 PFU) was incubated with 1 mM
VHH/antibody or 2.5 mM dextran sulfate (MP Biomedicals) for 30 min at room
temperature. The mixtures were added to chilled HEp-2 cells and incubated
for 2 h at 4 °C. The cells were washed ﬁve times with cold PBS with
0.5% BSA (PBS-BSA). Half of the cells were ﬁxed with 2% PFA, stained with
goat anti-RSV polyclonal serum (AB1128, Chemicon International) and
subsequently with AlexaFluor 488 labelled donkey anti-goat antibody
(Invitrogen, 1/600 dilution). After washing, the cells were analysed using
a FACSCalibur ﬂow cytometer. The other half of the cells was plated out and
incubated at 37 °C in DMEM with 2% FCS. After 48 h, the cells were collected,
ﬁxed and analysed as described above.

VHH binding to cells expressing F. HEK293T cells were transfected with
pCAGGS-F, which encodes a codon-optimized RSV F cDNA, with the FuGENE
HD transfection reagent (Promega) according to the manufacturer’s protocol.
To trace transfected cells, transfections were performed in the presence of
peGFP-NLS. Control transfections were performed with only peGFP-NLS.
Forty-two hours after transfection the cells were detached, washed and blocked.
Subsequently, the cells were incubated with a 1/10 dilution series of VHH or
mAb in PBS-BSA. One hour later the cells were washed and stained with mouse
anti-Histidine Tag antibody (MCA1396, Abd Serotec) followed by anti-mouse
IgG Alexa 633 (Invitrogen) (for the VHH samples) or anti-human IgG Alexa
633 (Invitrogen) (for the antibody samples). The stained cells were analysed
using a FACSCalibur ﬂow cytometer. All procedures were performed on ice
or at 4 °C.
Binding to infected cells was assessed in a similar manner. Vero cells were
inoculated with RSV A2 at a MOI of 0.1 and after 48 h the cells were collected
and ﬁxed with 2% PFA. The cells were stained with 1 mg ml 1 of VHH or antibody.
The rest of the staining procedure was performed as described above.

Immunostaining of infected cells. A549 cells, grown on glass plates for
confocal imaging or m-Dish glass bottom dishes (ibidi) for TIRF-imaging,
were mock-infected or infected with RSV A2 (MOI 1) for 24 h and ﬁxed with
2% PFA. The cells were blocked and stained with 1 mg ml 1 of F-VHH-4,
F-VHH-L66 or Ctrl-VHH in PBS-BSA. One hour later the cells were washed
and ﬁxed again with 2% PFA and stained with polyclonal goat anti-RSV serum
(or polyclonal rabbit anti-G serum (Sino Biological Inc. 11070-V08H) for the
TIRF images) and mouse anti-Histidine Tag antibody. VHH binding was
detected with anti-mouse IgG Alexa 488 and anti-RSV serum with anti-goat Alexa
633 (or anti-rabbit Alexa 568 for the TIRF images). After washing the samples were
mounted and confocal images were recorded with a SP5 Leica confocal microscope.
TIRF images were recorded with a Zeiss TIRF Observer. The recorded images were
processed with Volocity software (Perkin Elmer).

Cross-competition analysis with biolayer interferometry. Antibody crosscompetition was performed as described previously11 with some modiﬁcations.
Brieﬂy, DS-Cav1 protein (10 mg ml 1) was immobilized in a random orientation
on AR2G biosensors (ForteBio) pre-activated with N-hydroxysuccinimide (NHS)
and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) through amine
coupling reaction in acetate buffer (pH 5). The reaction was quenched by
1 M ethanolamine (pH 8) and DS-Cav1-immobilized biosensors were then
equilibrated with assay buffer (PBS with 1% BSA). The biosensors were dipped in
competitor antibodies (35 mg ml 1 in assay buffer) for 300 s followed by analyte
antibodies (35 mg ml 1 in assay buffer) for 300 s with a short baseline step (60 s)
in between the two antibody steps. All assays were performed at a set temperature
of 30 °C with agitation of 1,000 r.p.m. in an Octet HTX instrument (ForteBio).
Per cent inhibition of antibody binding by competing mAbs was calculated with
the following equation: Inhibition (%) ¼ 100  [(analyte antibody binding in the
presence competitor mAb)/(analyte antibody binding in the presence of isotype
control mAb)]  100.
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F-VHH escape mutant viruses. A dilution series of RSV A Long was used
to infect Vero cells in the presence of a dose corresponding to 20, 80 or 320 times
the IC50 of F-VHH-4 or F-VHH-L66. After 6 days of infection, the supernatant
of the cells infected with the highest dilution of RSV for which virus could be
detected (observed by plaque assay), was used to infect a subsequent series of
Vero cells in the presence of VHH or palivizumab. After two and four passages in
presence of F-VHH-L66 and F-VHH-4, respectively, single RSV isolates were
obtained by serial dilution which were ampliﬁed on Vero cells. Total RNA was
isolated from the resulting virus stocks, cDNA was prepared and the F gene was
ampliﬁed and sequenced with following FW and RV primers (50 ATCAAGCTTT
AACAATGGAGTTGCTAATCCTCA30 , 50 AACCGCTCGAGTTTAGTTACT
AAATGCAATAT30 ). A plaque-reduction assay with these virus isolates was
performed.
Surface plasmon resonance. Puriﬁed DS-Cav1 with a C-terminal Strep-tag II and
6X HisTag was captured on an NTA sensor chip to B530 response units (RU) each
cycle using a Biacore X100 (GE Healthcare). The NTA sensor chip was regenerated
between cycles using 0.25 M EDTA followed by 0.5 mM NiCl2. A buffer-only
sample was injected over the DS-Cav1 and reference ﬂow cells, followed by
F-VHH-4 or F-VHH-L66 2-fold serially diluted from 5 nM to 39.1 pM in
HBS-P þ , with a duplication of the 1.25 nM concentration. The data were doublereference subtracted and ﬁt to a 1:1 binding model using Scrubber.
Protein production for crystallization. Freestyle 293-F cells (R79007, Invitrogen)
were transfected with plasmid encoding stabilized prefusion RSV F (DS-Cav1)13.
Proteins were expressed in the presence of kifunensine (5 mM) and puriﬁed from
cell supernatants using Strep-Tactin resin (IBA). Tags were removed by thrombin
digestion and glycans were removed by digestion with Endo H (10% w/w) for 2 h at
room temperature. Puriﬁed DS-Cav1 was combined with a 1.5-fold and 2-fold
molar excess of Pichia-expressed F-VHH-4 and F-VHH-L66, respectively, and
separated from excess VHH using a Superose6 column (GE Healthcare
Biosciences). For crystallization trials of the unbound VHHs, vectors encoding
F-VHH-4 or -L66 with a C-terminal 3C cleavage site, Twin-Strep-tag and
8X HisTag were transfected into FreeStyle 293-F cells. Proteins were puriﬁed from
cell supernatants using Strep-Tactin resin before tag removal by HRV 3C digestion.
VHHs were separated from cleaved tags using a Superdex 75 column.
Crystallization and data collection. F-VHH-4 crystals were produced by sittingdrop vapour diffusion by mixing 100 nl of F-VHH-4 (9.45 mg ml 1) with 50 nl
of reservoir solution containing 3% (v/v) PEG 400, 2.2 M ammonium sulfate, 0.2 M
sodium chloride and 0.1 M HEPES pH 7.5. Crystals were soaked in reservoir
solution lacking 0.2 M sodium chloride and supplemented with 25% 2R,3Rbutanediol and frozen in liquid nitrogen. Diffraction data were collected to 1.87 Å
at SBC beamline 19-ID (Advanced Photon Source, Argonne National Laboratory).
Crystals of F-VHH-4 in complex with DS-Cav1 were produced by hangingdrop vapour diffusion by mixing 2 ml of the complex (2.45 mg ml 1) with 1 ml of
reservoir solution containing 0.2 M ammonium citrate pH 4.5, 14.75% (w/v)
PEG 3350 and 8.85% (v/v) isopropanol. Crystals were soaked in reservoir solution
supplemented with 30% (v/v) ethylene glycol and frozen in liquid nitrogen.
Diffraction data were collected to 3.3 Å at the GM/CA beamline 23-IDB
(APS, Argonne National Laboratory).
Crystals of F-VHH-L66 in complex with DS-Cav1 were produced by freeinterface diffusion by mixing 2 ml of the complex (4.79 mg ml 1) with 2 ml of
0.05 M potassium phosphate and 20% (w/v) PEG 4000 in a Crystal Former
Optimization Chip (Microlytic). Crystals were soaked in crystallization solution
supplemented with 30% (v/v) ethylene glycol and frozen in liquid nitrogen.
Diffraction data were collected to 3.8 Å at SBC beamline 19-ID.
Structure determination. All data were indexed and integrated in iMOSFLM43
and scaled and merged using AIMLESS44. F-VHH-4 crystals formed in space group
P212121 with near-perfect pseudo-merohedral twinning to appear as space group
P41212. Diffraction data from F-VHH-4 crystals were initially processed as P422
and a molecular replacement solution containing one VHH per asymmetric unit in
space group P41212 was obtained using PHASER45. However, reﬁnement resulted
in suspiciously high Rwork/Rfree values, particularly given the high resolution of this
data set. Evaluation of systematic absences revealed that 00 l reﬂections were
present for l ¼ 2n, which is compatible with a 42 or 21 screw axis, but not with the
41 axis found in the molecular replacement solution. Evaluation of the L- and
H-tests revealed that the crystal was pseudo-merohedrally twinned (Supplementary
Fig. 17a) with a twin fraction greater than 0.4 (Supplementary Fig. 17b). The data
were subsequently reprocessed in space group P212121 and a molecular
replacement solution was obtained containing two VHH molecules per asymmetric
unit. After manual model building in Coot46, the structure was reﬁned in
PHENIX47 to an Rwork/Rfree of 17.0/20.8% using twin law kh-l and a reﬁned twin
fraction of 0.47.
The F-VHH-4 and -L66 complexes formed crystals in space groups P3221 and
P3121, respectively. The unbound F-VHH-4 structure and the previously
solved prefusion F structure (PDB ID: 4MMS) were used as search models for
molecular replacement. The F-VHH-4 and -L66 structures were built manually in
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Coot and reﬁned with PHENIX using NCS torsion restraints and reference-model
restraints to an Rwork/Rfree of 18.4/23.4% and 24.8/28.6%, respectively. Complete
data collection and reﬁnement statistics are presented in Table 1 and stereo
views of a portion of the electron density for each structure are shown in
Supplementary Fig. 18.
HMPV microneutralization test. Predetermined amounts of GFP-expressing
hMPV recombinant viruses (NL/1/00 A1 sublineage or NL/1/99 B1 sublineage,
a kind gift of Bernadette van den Hoogen and Ron Fouchier, Rotterdam, the
Netherlands) or GFP-hRSV (A2 strain, a kind gift of Mark Peeples, Columbus,
Ohio, USA) were mixed with serial dilutions of VHH or monoclonal antibodies
before being added to cultures of Vero-118 cells. Forty-eight hours later, the
medium was removed, PBS was added and the amount of GFP per well was
measured with a Tecan microplate reader M200. Fluorescence values were
represented as per cent of a virus control without antibody and IC50 values were
calculated from the plotted curves.
Mice. Speciﬁc pathogen-free, female BALB/c mice were obtained from Charles
River (Charles River Wiga, Sulzfeld, Germany). The animals were housed in a
temperature-controlled environment with 12 h light/dark cycles; food and
water were provided ad libitum. The animal facility operates under the Flemish
Government License Number LA1400536. All experiments were done under
conditions speciﬁed by law and authorized by the Institutional Ethical Committee
on Experimental Animals (Ethical application EC2015-019).
Administration of VHHs and RSV A2 infection in mice. Mice, seven weeks
old, were randomly distributed in experimental groups of six animals. They
were slightly anesthetized by isoﬂurane before intranasal administration of VHH,
palivizumab or RSV challenge virus. VHH, palivizumab and RSV virus were
administered intranasally in a total volume of 50 ml PBS. Each group received
10 mg of F-VHH-4, 10 mg of Ctrl-VHH or 10 mg of palivizumab 4 h before infection
with 106 PFU of RSV A2. The mock-infected group received 10 mg of Ctrl-VHH
that is speciﬁc for a Junin virus protein.
Determination of lung viral titres by plaque assay. Five days after challenge,
mice were euthanized, lungs were removed and homogenized by vigorous shaking
with a Mixer Mill MM 2000 (Retsch) in the presence of a sterile metal bead in
1 ml HBSS containing 20% sucrose and supplemented with 1% penicillin and
1% streptomycin. Lung homogenates were cleared by centrifugation at 4 °C and
used to titrate the virus by plaque assay. We set lung homogenates in which no
virus was detected as the detection limit of the assay.
Determination of lung viral titre by qRT-PCR. To determine the lung RSV load
by qRT-PCR, total RNA from the cleared lung homogenates was prepared by using
the High Pure RNA Tissue Kit (Roche) according to the manufacturer’s instructions. Next, cDNA was prepared by the use of random hexamer primers and the
Transcriptor First Strand cDNA Synthesis Kit (Roche). The relative levels of
genomic RSV M cDNA were determined by qRT-PCR using primers speciﬁc for
the RSV A2 M gene (50 TCACGAAGGCTCCACATACA30 and 50 GCAGGG
TCATCGTCTTTTTC30 ) and a nucleotide probe (#150 Universal Probe Library,
Roche) labelled with ﬂuorescein (FAM) at the 50 -end and with a dark quencher
dye near the 30 -end. The qRT-PCR data were normalized to mRPL13A mRNA
levels.
Analysis of pulmonary cell inﬁltration. The immune cell composition of
bronchoalveolar lavages (BAL) was determined by analysing surface expression
of MHC-II, CD3e, SiglecF, CD4, CD8, CD11b and CD11c. Brieﬂy, highafﬁnity Fc receptors (FcRs) were blocked by incubation with puriﬁed
anti-mouse CD16/CD32 (Fc Block, BD Pharmingen, 553142) for 30 min
at 4 °C. Subsequently, the cells were stained with MHC-II-eFluor450
(eBioscience, 48-5321-82, 1/500), CD3e-AlexaFluor488 (BD Pharmingen,
557666, 1/300), SiglecF-PE (BD Pharmingen, 562068, 1/200), CD4-PerCP
(BD Pharmingen, 553052, 1/300), CD8-PE-Cy7 (eBioscience, 25-0081-81, 1/300),
CD11b-APC-Cy7 (BD Pharmingen, 557657, 1/500) and CD11c-APC
(BD Pharmingen, 550261, 1/200) for 1 h at 4 °C. After staining, samples were
measured on an LSR II ﬂow cytometer (BD Biosciences, San Jose, CA, USA),
and analysed using FlowJo X (TreeStar) software.
Testing lower doses of F-VHH-4 in mice. BALB/c mice, 7-weeks-old, were
slightly anesthetized by isoﬂurane before intranasal administration of VHH or
RSV challenge virus. VHH and RSV virus were formulated in PBS and administrated in a total volume of 50 ml, which was distributed equally over the two
nostrils. Each group of six mice received either 1, 3 or 10 mg of F-VHH-4 or
10 mg of Ctrl-VHH 4 h before infection with 106 PFU of RSV A2. The mockinfected group received 10 mg of Ctrl-VHH.
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Statistical analysis. We used Graphpad Prism 6 for statistical analyses, and
the two-sided Mann–Whitney U test to evaluate differences between two groups.
Data availability. Coordinates and structure factors for the unbound F-VHH-4,
and the F-VHH-4 and -L66 bound prefusion F complex structures have been
deposited in the Protein Data Bank under accession codes 5TP3, 5TOJ, and 5TOK,
respectively. All other relevant data are available from the authors upon request.
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its prefusion state
Iebe Rossey, Morgan S.A. Gilman, Stephanie C. Kabeche, Koen Sedeyn, Daniel Wrapp, Masaru Kanekiyo,
Man Chen, Vicente Mas, Jan Spitaels, José A. Melero, Barney S. Graham, Bert Schepens, Jason S. McLellan
& Xavier Saelens
Nature Communications 8:14158 doi: 10.1038/ncomms14158 (2017); Published 13 Feb 2017; Updated 29 Nov 2017.
In this Article, the clinical isolate MAD/GM3_10/14 of respiratory syncytial virus (RSV) is incorrectly described as an RSV A isolate.
MAD/GM3_10/14 has been identiﬁed as an RSV B isolate on the basis of its fusion protein sequence. The fusion protein sequences of
the clinical isolates used in this study have been deposited in GenBank under accession codes MF361899 (MAD/GM2_2/12),
MF361900 (MAD/GM2_12/12), MF361901 (MAD/GM2_13/12), MF361902 (MAD/GM2_14/12), MF361903 (MAD/GM3_10/14),
MF361904 (MON/9/92), and MF361905 (MAD/GM3_7/13).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in
a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
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